

PHARM**O**BEDIENT

August 24, 2023

Division of Dockets Management
U.S. Food and Drug Administration
Department of Health and Human Services
Room 1061, I-IFA-305
5630 Fishers Lane
Rockville, MD 20852

ANDA Suitability Petition for Diclofenac Potassium

Orally Disintegrating Tablets 25 mg and 50mg – Withdrawal Request

Reference: Suitability Petition - FDA-2022-P-0052

Dear Sir/Madam,

Per the communication from the Agency dated August 18, 2023, we hereby submit a withdrawal request for Suitability Petition FDA-2022-P-0052. We are planning to resubmit after October 1, 2023 to receive a goal date under a new suitability petition.

If there are any questions or comments, please do not hesitate to contact undersigned.

Sincerely,

Anthony LaViola
Principal Consultant
Pharmobedient Consulting
Regulatory/US Agent for Amici Pharmaceuticals, LLC
Tel. (954) 348-9455
Fax (413) 556-6632
Email: anthony@pharmobedient.com